Topic

Immunology & autoimmune: latest medical news

Autoimmune disease, immunology drugs and cell therapy outside cancer.

1. Saturday, October 24, 2026

   Patient dies in Bristol Myers Squibb autoimmune CAR-T trial

   Source: STAT

   STAT reports a patient death in a Bristol Myers Squibb trial of CAR-T therapy for an autoimmune condition, and asks where the safety bar should sit for these studies (full story is STAT+).

   Why it mattersAutoimmune patients are not facing the same risk-benefit trade-off as patients with refractory cancer, so serious events in this setting will shape regulator, IRB and sponsor tolerance for the whole CAR-T-in-autoimmunity field.

2. Saturday, October 24, 2026

   Remibrutinib versus teriflunomide in relapsing multiple sclerosis (REMODEL-1 and REMODEL-2)

   Source: The Lancet

   In two randomised trials, Novartis's oral BTK inhibitor remibrutinib was superior to teriflunomide in relapsing MS while maintaining a favourable safety profile, per the authors. STAT reports it cut relapse rates by a third versus the standard treatment.

   Why it mattersBTK inhibitors have faced liver-safety scrutiny as a class, so the hepatic safety detail in the full paper matters as much as efficacy for neurologists and drug-safety teams.